@inproceedings{inproceedings, title = {{Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)}}, url = {{}}, year = {{2021}}, month = {{1}}, author = {{Cork MJ and Thaci D and Eichenfield L and Arkwright PD and Chen Z and Delevry D and O'Malley JT and Bansal A}}, volume = {{85}}, journal = {{JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY}}, issue = {{3}}, pages = {{AB120-AB120}}, note = {{Accessed on 2025/04/11}}}